Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
Futamura M, Nakayama T, Yoshinami T, Oshiro C, Ishihara M, Morita M, Watanabe A, Tanigichi A, Tsukabe M, Shimoda M, Nitta K, Chihara Y, Yasojima H, Ouchi Y, Tokumaru Y, Masuda N. Futamura M, et al. Among authors: tsukabe m. Breast Cancer. 2023 Nov;30(6):943-951. doi: 10.1007/s12282-023-01485-y. Epub 2023 Jul 24. Breast Cancer. 2023. PMID: 37486454 Free PMC article.
Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H, Masuda N, Yamamoto D, Sagara Y, Sato N, Yamamoto Y, Saito M, Fujita T, Oura S, Watanabe J, Tsukabe M, Horiguchi K, Hattori S, Matsuura Y, Kuroi K. Iwata H, et al. Among authors: tsukabe m. Breast Cancer Res Treat. 2017 Apr;162(3):501-510. doi: 10.1007/s10549-017-4138-3. Epub 2017 Feb 8. Breast Cancer Res Treat. 2017. PMID: 28181129